Biotechnology

Neogen® Launches Petrifilm® Automated Feeder to Improve Efficiency of High-Throughput Food Safety Testing

Petrifilm end-to-end solution reduces hands-on enumeration time from 4 hours to 1 minute LANSING, Mich., June 27, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, is helping high-volume food safety testing laboratories implement a more effic...

2024-06-27 20:45 4260

Top 5 Global Biotech Company Goes Live with LifeSphere® MultiVigilance and Reporting & Analytics Solution

* The top-tier life sciences company will standardize its Safety operations on the cloud-powered technology platform, LifeSphere, which is propelling life sciences GenAI use cases. * The company will use LifeSphere MultiVigilance and Reporting & Analytics Solution to process some600,000 adver...

2024-06-27 20:00 2084

US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD

SHANGHAI, June 27, 2024 /PRNewswire/ -- Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvay...

2024-06-27 13:59 2374

HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002

HANGZHOU, China, June 26, 2024 /PRNewswire/ -- HUADONG MEDICINE, through its wholly-owned subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO. LTD (Zhongmei HuaDong), has recently announced positive results from Phase I clinical trials of its innovative oral small molecule GLP-1 receptor agoni...

2024-06-26 21:05 2544

TurtleTree Announces Strategic Partnership with Strive, a Sustainable Nutrition Company; Expands Consumer Product Offerings with LF+™ for Adult and Sports Nutrition

Strive and TurtleTree to Collaborate on a Immunity Support Beverage for Adults and a Protein Powder to be Made Available to the Public Q1 2025 SACRAMENTO, Calif. and SINGAPORE, June 26, 2024 /PRNewswire/ -- TurtleTree , a pioneer in sustainable nutrition, today announces ...

2024-06-26 21:01 3239

bioSeedin Expanded Global Licensing and Partnership Opportunities at 2024 BIO International Convention

NEWARK, Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a flourishing global licensing and consulting platform, captivated attendees as an esteemed exhibitor at the BIO International Convention, the preeminent global biotech gathering. This prestigious event unfolded inSan Diego, spanning from Jun...

2024-06-26 21:00 1271

Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau

The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase2b trial SYDNEY, ...

2024-06-26 20:56 2082

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimburse...

2024-06-26 16:44 3848

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 1759

Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services

SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. T...

2024-06-25 20:00 2080

CLL Community Urges Hospital Authority to List Next-Generation BTK Inhibitor on Drug Formulary to Bring Hope and Improve Quality of Life for CLL Patients

HONG KONG, June 25, 2024 /PRNewswire/ -- Chronic Lymphocytic Leukaemia ('CLL') is a lymphoproliferative disease characterised by the abnormal proliferation of lymphocytes. The progression of CLL is relatively slow and it is a mild haematological malignancy. Cypress Charitable Trust is aHong Kong ...

2024-06-25 17:00 1955

Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-06-25 08:00 2533

Science and Technology Daily: China's Fertile Grounds for Innovation

BEIJING, June 24, 2024 /PRNewswire/ -- On June 24, ten experts received the China International Science and Technology Cooperation Award at the National Science and Technology Award Conference inBeijing.   Science and Technology Daily: China's Fertile Grounds for Innovation They stand as eminen...

2024-06-24 21:41 2358

Bota Bio's Biomanufacturing Technology is Commercialized at NHU with A Successful Strategic Partnership Established

Bota's end-to-end bio-foundry tackles the challenge of transitioning from lab-developed technology to industrial-scale production, and empowers the rapid and efficient translation of cutting-edge biotechnology into tangible commercial value. SAN FRANCISCO, HANGZHOU and XINCHANG, China, June 24, ...

2024-06-24 21:00 1811

TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

* TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-lifein a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors * TiumBio presented interim Phase 1a clinical data of TU7710 and discussed pot...

2024-06-24 20:00 1826

iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson's Disease

WUHAN, China, June 24, 2024 /PRNewswire/ -- On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's Disease. This marks a significant milestone as NouvNeu001 becomes the wor...

2024-06-24 20:00 1629

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa

SINGAPORE, June 24, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling...

2024-06-24 09:00 1846

Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares

ROCKVILLE, Md. and SUZHOU, China, June 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK) announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of Amer...

2024-06-24 08:15 3214

Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference

* A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekl...

2024-06-22 07:00 5240

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.

2024-06-21 17:45 8526
1 ... 33343536373839 ... 312